

1 **Dynamic Analysis of Circulating Tumor DNA to Predict the**
2 **Prognosis and Monitor the Treatment Response of Patients**
3 **with Metastatic Triple-negative Breast Cancer: a prospective**
4 **study**

5
6 Yajing Chi^{1,2}, Mu Su³, Dongdong Zhou¹, Fangchao Zheng¹, Baoxuan Zhang¹, Ling
7 Qiang¹, Guohua Ren¹, Lihua Song¹, Bing Bu¹, Shu Fang¹, Bo Yu³, Jinxing Zhou³,
8 Jinming Yu^{4#}, Huihui Li^{1#}

9 1. Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical
10 University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.

11 2. School of Medicine, Nankai University, Tianjin, China

12 3. Department of Bioinformatics, Berry Oncology Corporation, Beijing, China.

13 4. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University
14 and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.

15 #Corresponding author:

16 Huihui Li, Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First
17 Medical University and Shandong Academy of Medical Sciences, No.440, Jiyan Road, Huaiyin District, Jinan,
18 Shandong Province, China, Zip: 250017, Tel: +86 15553103209, Email: huihuili82@163.com.

19 Jinming Yu, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical
20 University and Shandong Academy of Medical Sciences, Jinan, 250017, Shandong Province, China. Email:
21 sdyujinming@163.com.

22 **Abstract**

23 **Background:** Limited data are available on the application of circulating tumor DNA
24 (ctDNA) in metastatic triple-negative breast cancer (mTNBC) patients. Here, we
25 investigated the value of ctDNA for predicting the prognosis and monitoring the
26 treatment response in mTNBC patients.

27 **Methods:** We prospectively enrolled 70 Chinese patients with mTNBC who had
28 progressed after ≤ 2 lines of chemotherapy and collected blood samples to extract
29 ctDNA for 457-gene targeted panel sequencing.

30 **Results:** Patients with ctDNA+, defined by 12 prognosis-relevant mutated genes, had
31 a shorter progression-free survival (PFS) than ctDNA- patients (5.16 months vs. 9.05
32 months, $P = 0.001$) and ctDNA+ was independently associated with a shorter PFS (HR,
33 95%CI: 2.67, 1.2–5.96; $P = 0.016$) by multivariable analyses. Patients with a higher

34 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

35 (ctDNA% ≥ 0.05) had a significantly shorter PFS than patients with a lower MATH
36 score (5.67 months vs. 11.27 months, $P = 0.007$) and patients with a lower ctDNA%
37 (5.45 months vs. 12.17 months, $P < 0.001$), respectively. Positive correlations with
38 treatment response were observed for MATH score ($R = 0.24$, $P = 0.014$) and ctDNA%
39 ($R = 0.3$, $P = 0.002$), but not the CEA, CA125, or CA153. Moreover, patients who
40 remained ctDNA+ during dynamic monitoring tended to have a shorter PFS than those
41 who did not (3.90 months vs. 6.10 months, $P = 0.135$).

42 **Conclusions:** ctDNA profiling provides insight into the mutational landscape of
43 mTNBC and may reliably predict the prognosis and treatment response of mTNBC
44 patients.

45 **Funding:** This work was supported by the National Natural Science Foundation of
46 China (Grant No. 81902713), Natural Science Foundation of Shandong Province (Grant
47 No. ZR2019LZL018), Breast Disease Research Fund of Shandong Provincial Medical
48 Association (Grant No. YXH2020ZX066), the Start-up Fund of Shandong Cancer
49 Hospital (Grant No. 2020-PYB10), Beijing Science and Technology Innovation Fund
50 (Grant No. KC2021-ZZ-0010-1).

51 **Keywords:** Circulating tumor DNA; metastatic triple-negative breast cancer; next-
52 generation sequencing; prognosis; treatment response

53

54 **Introduction**

55 Breast cancer is the most common malignant tumor and the leading cause of cancer-
56 related deaths in women worldwide (Sung et al., 2021). Triple-negative breast cancer
57 (TNBC) represents 15%–20% of all breast cancer cases and exhibits a more aggressive
58 phenotype (with a poorer prognosis) than non-TNBC (Foulkes, Smith, & Reis-Filho,
59 2010; X. Li et al., 2017; Malorni et al., 2012). Due to the absence of human epidermal
60 growth factor receptor 2 (HER2), estrogen receptor (ER), or progesterone receptor (PR)
61 expression, TNBC lacks effective targeted therapies and treatment regimens. Patients
62 with mTNBC have fewer available treatment options and exhibit worse survival than
63 early-stage TNBC patients. Furthermore, TNBC is a highly heterogeneous disease,

64 resulting in substantial differences in the tumorigenesis, treatment response, and disease
65 progression among patients(Burstein et al., 2015; Jiang et al., 2019; Perou, 2011), which
66 undoubtedly poses great challenges in prognostic prediction of the mTNBC and
67 efficacy assessment for already limited treatment options. Unfortunately, reliable and
68 tailored biomarkers to predict the prognosis and monitor the treatment response of
69 patients with TNBC are yet to be established.

70 It has been a long-standing clinical management model to predict the prognosis of
71 patients with mTNBC and guide treatment decision-making through imaging
72 examination and mutational features obtained by tumor biopsy. Imaging usually only
73 provides the external characterization of the tumor, but can not reveal tumor internal
74 molecular characteristics. Given the heterogeneity of TNBC, it is not possible to obtain
75 an accurate and comprehensive picture of the mutational landscape using tissue biopsies
76 unless repeated multiple biopsies(Diaz & Bardelli, 2014), and most patients are
77 refractory to repetitive punctures.

78 Compared with tissue biopsies, “liquid biopsies” collect and analyze tumor-derived
79 substances, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs),
80 and exosomes (e.g., from the blood, cerebrospinal fluid, and urine) of cancer patients
81 in a minimally invasive fashion(Alix-Panabières & Pantel, 2016; Palmirotta et al., 2018;
82 Poulet, Massias, & Taly, 2019). It can be used for early diagnosis of tumor patients,
83 predicting tumor recurrence and metastasis, and evaluating the characteristics and
84 clonal evolution of tumor genomes. ctDNA is a specific fraction of cell-free DNA
85 (cfDNA), which is present in the plasma of apoptotic and necrotic tumor cells(Swarup
86 & Rajeswari, 2007). Owing to special biological origin and the potential for multiple
87 repeat sampling, ctDNA is independent of tumor spatial and temporal heterogeneity,
88 convey more valuable information than a conventional tumor biopsy and enable the
89 dynamic monitoring of tumor burden and treatment response(Campos-Carrillo et al.,
90 2020; Chae & Oh, 2019; Dawson et al., 2013; Gerratana et al., 2021). The value of
91 ctDNA in the accurate prediction of drug resistance and clinical outcomes has also been
92 noted(Asante, Calapre, Ziman, Meniawy, & Gray, 2020; Murtaza et al., 2013).

93 Several studies have demonstrated the prognostic and predictive value of ctDNA for

94 non-mTNBC during or after (neo)adjuvant therapy(Cavallone et al., 2020; H. Kim et
95 al., 2021; Lin et al., 2021; Ortolan et al., 2021; Riva et al., 2017). Previously, researchers
96 have also been relatively circumscribed concentrated on evaluating specific copy
97 number variants (CNVs) or ctDNA-based single mutation or clonal evolution or the
98 ctDNA level to predict the prognosis of mTNBC patients and the efficacy of specific
99 treatment regimens(Barroso-Sousa et al., 2022; Chopra et al., 2020; Collier et al., 2021;
100 Stover et al., 2018; Weber et al., 2021; Wongchenko et al., 2020). Even a study showed
101 that the ctDNA level had no prognostic impact on survival of patients with
102 mTNBC(Madic et al., 2015). A more comprehensive study of the mutational
103 information and related markers embodied in ctDNA as well as a consensus on the
104 predictive role of ctDNA in mTNBC are needed to apply ctDNA in clinical practice.

105 Hence, in this study, we investigated the mutational characteristics of ctDNA and
106 ctDNA-related markers in mTNBC using targeted, capture-based, next-generation
107 sequencing (NGS), which offers rapid identification and high coverage from a small
108 blood sample. We aimed to dynamically and more comprehensively evaluate the value
109 of ctDNA in predicting the prognosis and monitoring the treatment response of patients
110 with mTNBC.

111

112 **Methods**

113 **Study design and sample collection**

114 Between 2018 and 2021, patients with mTNBC who had progressed after ≤ 2 lines of
115 chemotherapy were prospectively enrolled. A 10 mL sample of peripheral blood was
116 collected into an EDTA anticoagulant tube (STRECK Cell-Free DNA BCT[®]) from
117 patients at different time points (i.e., before treatment, during treatment [treatment cycle
118 3, day 1], and at progression). Within 2 hours of collection, blood samples were
119 centrifuged at $1,600 \times g$ for 10 min at 4 °C to obtain plasma, followed by secondary
120 centrifugation at $16,000 \times g$ for 10 min at 4 °C to obtained peripheral blood cells.
121 Plasma and peripheral blood cells were stored at -80 °C until the extraction of ctDNA
122 and genomic DNA (gDNA). Paraffin-embedded primary or metastatic tumor tissues
123 were collected before treatment and stored at room temperature for later use.

124

125 **DNA extraction and targeted capture-based NGS**

126 ctDNA was extracted from peripheral blood using the QIAamp Circulating Nucleic
127 Acid Kit (Qiagen, Germany) while tumor DNA (tDNA) was extracted from the
128 paraffin-embedded tumor tissues using the AllPrep DNA/RNA FFPE Kit (50) (Qiagen,
129 Germany). Normal control gDNA was extracted from white blood cells using the
130 DNeasy Kit (Qiagen, Germany) according to the manufacturer's instructions. The
131 sequencing library was prepared from the ctDNA and tDNA samples using the KAPA
132 DNA Library Preparation Kit (KAPA Biosystems, USA), while the gDNA sequencing
133 library was constructed using the Illumina TruSeq DNA Library Preparation Kit
134 (Illumina, USA). Library concentration was determined using real-time quantitative
135 PCR and the KAPA Library Quantification Kit (KAPA Biosystems, USA). The library
136 fragments were then size-selected using agarose gel electrophoresis. A targeted NGS
137 panel of 457 genes (**Supplementary Table 1**), which are known to be frequently
138 mutated in tumors, was designed to capture the target DNA fragments. Sequencing
139 libraries were loaded onto a NovaSeq 6000 platform (Illumina, USA) with a 150-bp
140 read length in paired-end mode.

141

142 **Sequencing data analysis**

143 Quality control of the raw sequencing data involved the use of FASTP to trim adapters
144 and remove low-quality sequences(Chen, Zhou, Chen, & Gu, 2018). The clean reads
145 were aligned against the Ensemble GRCh37/hg19 reference genome using BWA
146 software(H. Li & Durbin, 2009). PCR duplications were processed using the gencore
147 tool(Chen et al., 2019) and uniquely mapped reads were generated. The SAMtools suite
148 was used to detect single-nucleotide variants (SNVs), insertions, and deletions(H. Li et
149 al., 2009). CNVs were called using CONTRA(J. Li et al., 2012), with copy number >
150 3 as the threshold of copy number gain and < 1 as the threshold of copy number loss.
151 The maximal tumor somatic variant allelic frequency (max-VAF) describes the highest
152 mutated frequency of ctDNA detected in the cfDNA(Maron et al., 2019). The
153 calculation of the ctDNA fraction (ctDNA%) was based on the autosomal somatic allele

154 fractions. The mutant allele fraction (MAF) and ctDNA% are related as follows: MAF
155 = $(\text{ctDNA} \times 1)/[(1 - \text{ctDNA}) \times 2] + [\text{ctDNA} \times 1]$; thus, $\text{ctDNA} = 2/(1/\text{MAF} +$
156 $1)$ (Vandekerkhove et al., 2017). The mutant-allele tumor heterogeneity (MATH) score
157 was calculated as the percentage ratio of the width (median absolute deviation [MAD]
158 scaled by a constant factor, so that the expected MAD of a sample from a normal
159 distribution equals the standard deviation) to the center of the distribution of MAFs
160 among the tumor-specific mutated loci; thus, $\text{MATH} = 100 \times \text{MAD}/\text{median}$ (Mroz &
161 Rocco, 2013). Tumor mutational burden (TMB) was defined as the number of non-
162 synonymous somatic mutations per megabase of genome examined(Chalmers et al.,
163 2017).

164

165 **Statistical analysis**

166 The longest diameter (mm) of the tumor was measured by examining the radiological
167 images. The response evaluation was carried out according to the Response Evaluation
168 Criteria in Solid Tumors (RECIST) guidelines (version 1.1)(Eisenhauer et al., 2009).
169 The Kaplan–Meier method was used for the survival analyses; median comparison was
170 performed using the log-rank test and hazard ratios (HRs) from the Cox proportional
171 hazards model. The optimal cut-off values for ctDNA%, MATH score, and TMB were
172 determined by the R package “survminer”. Progression-free survival (PFS) was defined
173 as the time interval from the initiation of the study to disease progression or death from
174 any cause. Univariate Cox regression was carried out to analyze the mutations related
175 to PFS; only genes mutated in > 5% of the patients were included in the analysis. The
176 correlation between variables was analyzed using the Spearman correlation test and
177 group comparisons were performed using the Wilcoxon rank-sum test. Statistical
178 analysis and data visualization were conducted using R (version 4.0.1). The statistical
179 significance was defined as bilateral $P < 0.05$.


180

181 **Results**

182 **Study cohort and sample information**

183 A total of 126 patients with mTNBC were included in the study. Fifty-six patients were
184 excluded, comprising 21 patients who had previously been treated with more than two
185 lines of chemotherapy, 16 patients who were treated with combination therapy (e.g.,
186 chemotherapy with radiotherapy), 11 patients who were lost to follow-up, and 8 patients
187 who failed to be evaluated for efficacy. Finally, 139 plasma samples (baseline samples
188 from 70 patients and dynamic samples from 38/70 patients) from 70 patients and paired
189 tumor tissues from 13 patients were collected and sequenced (**Figure 1A, B**). The
190 patient baseline characteristics are shown in **Table 1**. The median age of all patients
191 was 46 (26–75) years. Overall, 82.9% of patients were diagnosed with invasive ductal
192 carcinoma and most of the patients developed visceral metastases at study entry. **Table**
193 **2** shows that all patients received chemotherapy-based treatment with the most common
194 chemotherapy drugs, such as gemcitabine, taxane, or platinum. Eleven patients were
195 also treated with immunotherapy. The objective response rate was 38.6%, and 4, 23, 31,
196 and 12 patients had complete response (CR), partial response (PR), stable disease (SD),
197 and progressive disease (PD), respectively. The median PFS (mPFS) for all patients was
198 6.15 months (**Supplementary Figure 1A**). There was no significant difference in PFS
199 among different treatment lines or regimens (**Supplementary Figure 1B-H**), although
200 patients treated in the first line had a trend towards improved survival compared with
201 those treated in the second and third lines.

Figure 1



202

203

204

205

206

207

208

209

210

Figure 1. Study design and sample collection. (A) Study flowchart. After excluding 82 patients, a total of 70 patients with mTNBC were included in the final analysis. Baseline blood samples were collected from all patients (n = 70) and paired tumor tissues were collected from 13 patients for NGS. (B) Blood-sample-derived ctDNA was dynamically monitored at baseline (yellow), during treatment (green), and at progression (orange) for 38 of the 70 patients. ctDNA, circulating tumor DNA; mTNBC, metastatic triple-negative breast cancer; NGS, next-generation sequencing.

211 Table 1. The baseline characteristics in study population.

Characteristics	All patients-no. (%) (n=70)	Dynamic monitoring patients-no. (%) (n=38)
Age (yrs), median (range)	46 (26-75)	47 (27-75)
≤50	45 (64.3)	26 (68.4)
>50	25 (35.7)	12 (31.6)
Histopathologic diagnosis		
Invasive ductal carcinoma	58 (82.9)	29 (76.3)
Other	10 (14.3)	7 (18.4)
NA	2 (2.9)	2 (5.3)
Pathological grade		
I-II	12 (17.1)	10 (26.3)
III	39 (55.7)	20 (52.6)
NA	19 (27.1)	8 (21.1)
Disease stage at initial diagnosis		
I	7 (10.0)	5 (13.2)
II	20 (28.6)	10 (26.3)
III	33 (47.1)	20 (52.6)
IV	7 (10.0)	3 (7.9)
NA	3 (4.3)	0
Disease-free interval (months)		
≤12 (including stage IV at initial diagnosis)	23 (32.9)	11 (28.9)
>12	47 (67.1)	27 (71.1)
Sites of metastasis		
Visceral	56 (80.0)	33 (86.8)
Non-visceral	14 (20.0)	5 (13.2)
Previous lines of chemotherapy during metastatic stage		
0	46 (65.7)	22 (57.9)
1	19 (27.1)	11 (28.9)
2	5 (7.1)	5 (13.2)

212

213

214

215

216

217

218

219

220

221

222

223

224 Table 2. The treatment characteristics and responses of patients.

Treatment characteristics and responses	All patients-no. (%) (n=70)	Dynamic monitoring patients-no. (%) (n=38)
Treatment regimens		
Contained gemcitabine + platinum	17 (24.3)	10 (26.3)
Contained taxane + platinum	16 (22.9)	7 (18.4)
Contained vinorelbine + platinum	4 (5.7)	1 (2.6)
Contained taxane but no platinum	22 (31.4)	14 (36.8)
Other	11 (15.7)	6 (15.8)
Treatment modalities		
Immunotherapy + chemotherapy	11 (15.7)	6 (15.8)
Chemotherapy	59 (84.3)	32 (84.2)
Treatment responses		
CR	4 (5.7)	4 (10.5)
PR	23 (32.9)	9 (23.7)
SD	31 (44.3)	18 (47.4)
PD	12 (17.1)	7 (18.4)

225


226 Mutation characteristics of patients with mTNBC

227 Plasma samples were obtained from 70 patients with mTNBC before treatment and
 228 submitted for targeted NGS. In total, 203 mutated genes were identified using our panel
 229 of 457 genes, including 301 missense mutations, 45 frame-shift indels, 16 in-frame
 230 indels, 13 splice-site mutations, and 31 stop-gain mutations. The ten most frequently
 231 mutated genes were *TP53* (69%), *PIK3CA* (24%), *ARID1A* (9%), *KMT2C* (9%), *CIC*
 232 (7%), *KMT2D* (7%), *NOTCH4* (7%), *PBRM1* (7%), *PTEN* (7%), and *DNMT3A* (6%).
 233 In addition, gene CNVs were detected in 351/457 genes, 296 of which showed copy
 234 number gain (CNG), 38 showed copy number loss, and 17 had both gain and loss
 235 mutations. The most prevalent genes with CNVs were *HLA-C* (50%), *HLA-A* (33%),
 236 *HLA-B* (33%), *HLA-DRB1* (23%), *SPPL3* (21%), *BTG2* (19%), *C8orf34* (16%), *HLA-*
 237 *DQA1* (16%), *HLA-E* (16%), and *LTBP1* (16%) (**Figure 2A**).

238 We also used NGS to evaluate the discrepancy and consistency of genomic
 239 alterations in ctDNA samples and paired tumor tissues from 13 patients. The mutation
 240 frequency in plasma ctDNA was significantly lower than that in the tumor tissues (0.049%
 241 \pm 0.113% vs. $0.168 \pm 0.173\%$, $P < 0.001$) (**Supplementary Figure 2**). A total of 115
 242 mutations in 85 genes were detected, which included 84 mutations in 63 genes from

243 plasma ctDNA and 81 mutations in 55 genes from tDNA. The number of ctDNA-
 244 specific and tDNA-specific mutated genes was 37 in both cases. Hence, the
 245 concordance rate between mutations in ctDNA and tDNA was 98.75% (**Figure 2B**).

Figure2



246

247 **Figure 2. Mutation characteristics of patients with mTNBC.** (A) The landscape of ctDNA mutations in 70 patients
 248 with mTNBC prior to treatment initiation. The patients (n = 70) were divided into four groups (PD, SD, PR, and CR)
 249 according to the best treatment response (from left to right). The top half of the figure shows SNVs with a mutation
 250 frequency $\geq 5\%$, and the bottom half shows CNVs with a mutation frequency $\geq 10\%$; the different colored rectangles
 251 represent different types of variation. (B) Concordance between the genomic alterations in the blood-derived ctDNA
 252 and the tissue-derived tDNA. The mutated genes detected in at least two samples are shown here. The concordance
 253 rate = shared mutated genes / (all genes \times the number of comparisons) $\times 100\%$ = $(1 - [\text{ctDNA-specific and tissue-}$
 254 $\text{specific mutated genes}] / [\text{all genes} \times \text{the number of comparisons}]) \times 100\%$ = $(1 - [37 + 37] / [457 \times 13]) \times 100\%$ =
 255 98.75%. CNVs, copy number variants; CR, complete response; ctDNA, circulating tumor DNA; tDNA, tumor DNA;

256 mTNBC, metastatic triple-negative breast cancer; PD, progressive disease; PR, partial response; SD, stable disease;
257 SNVs, single-nucleotide variants.

258


259 **A ctDNA+/- status correlates with the treatment response and survival of** 260 **patients with mTNBC**

261 Univariate Cox regression analysis showed that 12 mutated genes, including *HLA-B*
262 (HR, 95% confidence interval [CI]: 1.89, 1.08–3.32), *BTG2* (HR, 95% CI: 2.23, 1.15–
263 4.31), *MCL1* (HR, 95% CI: 2.31, 1.1–4.84), *H3F3A* (HR, 95% CI: 2.36, 1.08–5.16),
264 *MYC* (HR, 95% CI: 3.45, 1.58–7.54), *KMT2C* (HR, 95% CI: 2.75, 1.14–6.63), *KYAT3*
265 (HR, 95% CI: 3.66, 1.48–9.04), *ARID4B* (HR, 95% CI: 4.04, 1.51–10.76), *CD22* (HR,
266 95% CI: 3.66, 1.25–10.68), *TGFBI* (HR, 95% CI: 3.94, 1.35–11.56), *SGK1* (HR, 95%
267 CI: 3.37, 1.15–9.82), and *RSPO2* (HR, 95% CI: 4.19, 1.42–12.34), indicated a higher
268 risk for recurrence or progression in patients with mTNBC (**Figure 3A**). Moreover,
269 these 12 mutated genes were significantly associated with worse survival
270 (**Supplementary Figure 3**).

271 ctDNA was collected and evaluated at different time points and a plasma ctDNA
272 sample with at least one of the 12 prognosis-relevant mutated genes was defined as
273 ctDNA-positive (ctDNA+) (**Figure 3B**). The right half of **Figure 3B** shows that the
274 mPFS in 70 patients with mTNBC was 6.15 months at a median follow-up of 19.13
275 months. As shown, ctDNA+ patients tended to have a shorter survival duration and less
276 clinical benefit. At baseline, the ctDNA+ rates were 25%, 43%, 55%, and 33% in
277 patients with CR, PR, SD, and PD, respectively. By comparing the ctDNA+/- status at
278 all the time points, we found that the amount of ctDNA+ positively correlated with a
279 worse treatment response. The proportion of ctDNA+ at different time points was 46%
280 (at baseline), 29% (during treatment), and 44% (at progress), while that in the different
281 treatment response groups was 45% (PD), 39% (SD), 22% (PR), and 0% (CR) (**Figure**
282 **3C**). Prior to treatment, the tumor size of the ctDNA+ group was significantly larger
283 than that of the ctDNA- group (52.56 ± 34.65 mm vs. 40.18 ± 35.49 mm, $P < 0.001$)
284 (**Figure 3D**). We also found that patients who were ctDNA+ at baseline had a shorter
285 PFS than those who were ctDNA- at baseline (5.16 months vs. 9.05 months, $P = 0.001$)

286 (Figure 3E). Multivariate Cox regression analysis, which included multiple clinical
 287 factors and ctDNA status, showed that ctDNA+ was independently associated with a
 288 shorter PFS (HR, 95% CI: 2.67, 1.2–5.96; $P = 0.016$) (Table 3).

Figure3



289

290 **Figure 3. Prognostic relevance of mutations in patients with mTNBC.** (A) Twelve mutated genes, comprising
 291 *HLA-B* (CNG), *BTG2* (CNG), *MCL1* (CNG), *H3F3A* (CNG), *MYC* (CNG), *KMT2C* (SNV), *KYAT3* (CNG), *ARID4B*
 292 (CNG), *CD22* (CNG), *TGFB1* (CNG), *SGK1* (CNG), and *RSPO2* (CNG) were identified as being associated with a
 293 higher risk of recurrence or progression in patients with mTNBC (all had HRs > 1 and a $P < 0.05$). (B) The left half
 294 of the figure summarizes the ctDNA status of all patients ($n = 70$) at different time points; among these, 38 patients
 295 also had their ctDNA status recorded during treatment and at progression. Solid dots represent ctDNA+ patients,
 296 while unfilled dots represent ctDNA- patients. The length of line segments in the right half of the figure denotes the
 297 PFS of patients, whereby the bars indicate the best response (PD, SD, PR, or CR) observed during treatment. (C)
 298 Comparison of ctDNA status (ctDNA+, red; ctDNA-, blue) among all the blood samples ($n = 139$) from patients

299 with different treatment responses (PD, SD, PR, or CR). (D) The tumor size of the ctDNA+ group at baseline was
 300 significantly greater than that of the ctDNA- group at baseline. (E) ctDNA+ at baseline was significantly associated
 301 with a shorter PFS. CNG, copy number gain; CR, complete response; ctDNA, circulating tumor DNA; ctDNA-,
 302 ctDNA negative; ctDNA+, ctDNA positive; HR, hazard ratio; mTNBC, metastatic triple-negative breast cancer; PD,
 303 progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SNV, single-nucleotide
 304 variant. A *P*-value < 0.05 was used as a measure of statistical significance.

305

306 Table 3. Multivariate cox regression analysis of multiple clinical factors and ctDNA
 307 status with PFS of patients.

Variable	HR (95 CI)	p value
Age (≤ 50 vs. > 50 years)	1.21 (0.47-3.1)	0.694
Histopathologic diagnosis (IDC vs. non-IDC)	0.64 (0.15-2.73)	0.55
Pathological grade (III vs. I-II)	1.23 (0.53-2.86)	0.629
DFI (≤ 12 months vs. > 12 months)	1.69 (0.6-4.71)	0.319
ctDNA status (ctDNA+ vs. ctDNA-)	2.67 (1.2-5.96)	0.016
T stage (T1 vs. T2 vs. T3)	0.75 (0.38-1.47)	0.397
N stage (N1 vs. N2 vs. N3)	0.79 (0.57-1.1)	0.161
CEA elevation (Yes vs. No)	1.75 (0.64-4.81)	0.278
CA125 elevation (Yes vs. No)	0.67 (0.24-1.88)	0.445
CA153 elevation (Yes vs. No)	1.86 (0.62-5.57)	0.268
Ki-67 ($\geq 30\%$ vs. $< 30\%$)	0.78 (0.33-1.88)	0.582
Site of metastasis (visceral vs. non-visceral)	0.54 (0.18-1.61)	0.267
TMB (High vs. Low)	1.08 (0.38-3.09)	0.88


308

309 **Baseline ctDNA-related markers are associated with mTNBC patient** 310 **survival and treatment response**

311 To further explore the value of ctDNA in predicting clinical outcomes in mTNBC, we
 312 examined the association between the pre-treatment ctDNA-related markers (i.e., TMB,
 313 MATH score, and ctDNA%) and PFS and the treatment response. Thus, we performed
 314 Kaplan–Meier analyses of TMB, MATH score, ctDNA%, and PFS in patients with
 315 mTNBC. Although not statistically significant, TMB-high (≥ 2.63) patients tended to
 316 have a shorter mPFS than the TMB-low (< 2.63) patients (5.87 months vs. 10.03 months,
 317 $P = 0.057$) (**Figure 4A**). Meanwhile, patients with a higher MATH score (≥ 6.316) had
 318 significantly shorter mPFS than patients with a lower MATH score (< 6.316) (5.67
 319 months vs. 11.27 months, $P = 0.007$) (**Figure 4B**). Moreover, the higher ctDNA% (\geq
 320 0.05) patient group had a significantly shorter mPFS than the lower ctDNA% (< 0.05)

321 group (5.45 months vs. 12.17 months, $P < 0.001$) (**Figure 4C**). Patients with mTNBC
 322 were categorized into the PD, SD, PR, and CR groups according to their response to
 323 treatment. Further comparative analysis of baseline ctDNA parameters in different
 324 treatment response groups revealed that TMB was progressively lower across the four
 325 groups, showing a decreasing trend from the PD group to the CR group. Compared with
 326 other treatment response groups, the PD group had a larger TMB ($P = 0.032$), greater
 327 MATH score ($P = 0.003$), and higher ctDNA% ($P = 0.002$) (**Figure 4D–F**).

Figure 4



328
 329 **Figure 4. The baseline-ctDNA-derived TMB, MATH score, and ctDNA% were associated with the clinical**
 330 **outcomes of patients with mTNBC.** Higher TMB (≥ 2.63) (A), MATH score (≥ 6.316) (B), and ctDNA% (≥ 0.05)
 331 (C) were linked to a shorter PFS. The optimal cut-off values for TMB, MATH score, and ctDNA% were determined
 332 using the R package “survminer”. Comparison of TMB (D), MATH score (E), and ctDNA% (F) in patients with
 333 different treatment responses (PD, SD, PR, or CR). CR, complete response; ctDNA, circulating tumor DNA;
 334 ctDNA%, ctDNA fraction; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free survival; PD,
 335 progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden. A P -value < 0.05 was
 336 used as a measure of statistical significance.


337

338 **Dynamic changes in ctDNA are associated with treatment response of**
 339 **patients with mTNBC**

340 **Figure 5A–D** highlight the dynamic changes in ctDNA levels (i.e., mutations in 12
 341 prognosis-relevant genes) and traditional tumor markers in each patient with PD
 342 (Patient 32), SD (Patient 31), PR (Patient 29), or CR (Patient 18). For instance in Patient
 343 32, the MAF of *MYC* ctDNA increased significantly and was accompanied by increased

344 CA125 and CA153 levels and decreased CEA levels at the time of disease progression
345 (**Figure 5A**). **Figure 5B–D** shows evidence of ctDNA mutations in Patient 31 (*BTG2*,
346 *ARID4B*, *CD22*, *H3F3A*, *HLA-B*, *MCL1*, *MYC*, *RSPO2*), Patient 29 (*BTG2*, *ARID4B*,
347 *H3F3A*, *HLA-B*, *MCL1*, *MYC*), and Patient 18 (*BTG2*, *ARID4B*, *H3F3A*, *HLA-B*,
348 *SGKI*); their mutational rates dropped to the lowest level during the best response to
349 treatment and rose again during progression. CA125 levels varied in line with treatment
350 response and progression but no similar fluctuations were observed for CA153 and
351 CEA. However, compared with the traditional tumor markers, dynamic changes in
352 ctDNA mutations seemed to better mirror treatment-induced changes in tumor size. We
353 therefore analyzed the correlation between the levels of serum tumor markers and tumor
354 size on computed tomography (CT) scans during treatment (**Figure 5E**). We found that
355 tumor size positively correlated with the MATH score ($R = 0.24$, $P = 0.014$) and ctDNA%
356 ($R = 0.3$, $P = 0.002$), but not CEA, CA125, or CA153 levels. There were also strong
357 positive correlations among the three ctDNA-related markers, TMB, MATH score, and
358 ctDNA%. Moreover, the dynamic changes in ctDNA status may predict the prognosis
359 of mTNBC. Kaplan–Meier analysis found that patients who remained ctDNA+ during
360 dynamic monitoring had a shorter PFS than those who did not (3.90 months vs. 6.10
361 months, $P = 0.135$) (**Figure 5F**); however, this difference did not achieve statistical
362 significance, most likely due to the limited sample size.

Figure5



363
 364 **Figure 5. Dynamic ctDNA changes in patients with mTNBC.** (A–D) Dynamic changes in tumor size were
 365 observed using computed tomography (CT) scans and the conventional tumor markers CEA, CA125, and CA153
 366 (left side) or the VAF/copy number of 12 prognosis-relevant genes (right side) in four patients who each had a
 367 different best treatment response: PD (Patient 32), SD (Patient 31), PR (Patient 29), and CR (Patient 18). (E) The
 368 correlation between tumor size (measured using CT scans) and conventional tumor markers (CEA, CA125, CA153)
 369 or ctDNA parameters (TMB, MATH score, ctDNA%). Blue: positive correlation; red: negative correlation (the
 370 stronger the correlation, the darker the color). (F) Patients with a ctDNA+ status across all time points (All positive)
 371 tended to have a shorter PFS than those who were ctDNA– at least once during the process of dynamic monitoring
 372 (Other). CR, complete response; ctDNA, circulating tumor DNA; ctDNA–, ctDNA negative; ctDNA+, ctDNA
 373 positive; ctDNA%, ctDNA fraction; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free
 374 survival; PD, progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden; VAF,
 375 variant allelic frequency. A *P*-value < 0.05 was used as a measure of statistical significance.

376

377 Discussion

378 Since the advent of precision medicine, liquid biopsies have become more widely
379 utilized in the clinical management of cancer. In recent years, ctDNA has become the
380 focus of extensive research as a predictive biomarker of tumor progression and/or
381 treatment response. Several studies have explored the promising applications of ctDNA
382 in breast cancer. For example, some researchers have investigated the longitudinal
383 dynamics of ctDNA in the treatment monitoring of metastatic breast cancer, while
384 others have studied the prognostic and predictive value of ctDNA during neoadjuvant
385 chemotherapy for TNBC(Cavallone et al., 2020; Gerratana et al., 2021; Ortolan et al.,
386 2021; Riva et al., 2017). However, the application of ctDNA in monitoring mTNBC is
387 rare in clinical practice.

388 In the current study, we performed targeted, capture-based NGS (with a 457-gene
389 panel) on 139 plasma samples obtained by liquid biopsy from 70 patients with mTNBC.
390 Thirteen paired tumor tissues were also analyzed to verify if ctDNA could be a feasible
391 alternative to tumor-tissue-derived tDNA. This study demonstrated how a ctDNA-
392 based platform could reliably reveal mutational profiles, stably predict the prognosis,
393 and consistently monitor the treatment response of patients with mTNBC. This study
394 also resolved the uncertainty of some current studies regarding the value of ctDNA and
395 provided clear ctDNA-related predictive markers for mTNBC patients. By evaluating
396 the mutational landscape of mTNBC in the Chinese population using ctDNA analysis,
397 we showed that the most frequently mutated genes were *TP53*, *PIK3CA*, *ARID1A*, and
398 *KMT2C*, and the most frequent CNV was detected in *HLA-C*, *HLA-A*, *HLA-B*, and *HLA-*
399 *DRB1* (**Figure 2A**). These genes play significant roles in the tumorigenesis, progression,
400 invasion, and metastasis of breast cancer. In the homogeneous population, the most
401 common mutations detected in tumor tissue were *TP53*, followed by *PIK3CA*, *KMT2C*,
402 and *PTEN*; however, the top-ranking CNVs were found in different genes to those
403 identified in a previous report: *E2F3*, *IRS2*, *CCNE1*, *EGFR*, *NFIB*, *CCND1*, and
404 *MYB*(Jiang et al., 2019). This difference may be due to the fact that the plasma-derived
405 ctDNA contains smaller fragments than those that are typically found in tissue-derived
406 tDNA. Meanwhile, compared with the results of other ctDNA identification studies, the
407 distribution of frequent variants in the TNBC cohort was overall consistent(Davis et al.,

408 2020; Rong et al., 2020; Wang et al., 2021). In the study by Chae et al., the concordance
409 between all ctDNA- and tDNA-derived genes was also similar to that in our study
410 (91.0%–94.2% vs. 98.75%)(Chae et al., 2017) (**Figure 2B**). The authors reported that
411 the ctDNA-based assay had a high specificity, with a diagnostic accuracy of up to 80%.
412 Although the mutation frequency of tDNA was higher than that of ctDNA in our study,
413 the number of mutations detected in both types of DNA was similar. In addition, we
414 detected 37 specific mutations in each of the ctDNA and tDNA groups, demonstrating
415 the complementarity of blood-derived ctDNA and tissue-derived tDNA. Moreover,
416 compared with tumor tissue analysis, ctDNA assays only require a small blood sample,
417 can capture a variety of mutations (including SNVs and CNVs), and provide
418 information on spatial tumor heterogeneity.

419 Using NGS, we identified 12 prognosis-relevant mutated genes, which were
420 associated with the shorter PFS of patients with mTNBC (**Supplementary Figure 3**).
421 Most of the 12 genes have been linked to breast cancer by previous studies. For instance,
422 the aberrant expression of *KMT2C* (low expression) and *ARID4B* (high expression)
423 contribute to the poor prognosis of patients with ER-positive breast cancer(Sato &
424 Akimoto, 2017; J. Zhang et al., 2021). However, previous studies have shown that the
425 upregulated expression of *BTG2* and *CD22* were associated with improved survival,
426 which is not in agreement with our current findings(Mascia et al., 2022; Y. J. Zhang et
427 al., 2013); this may be due to the low number of patients included in this study. *TGFBI*,
428 *SGKI*, *RSPO2*, and *MCL1* are implicated in the invasion, migration, growth, autophagy,
429 and progression of TNBC, while *RSPO2* and *MCL1* overexpression is associated with
430 shorter survival rates in patients with TNBC(Coussy et al., 2017; S. Kim, Lee, Jeon,
431 Nam, & Lee, 2015; Yang et al., 2014; Zhu et al., 2020).

432 As a common driver of breast cancer, *MYC* amplification plays a role in emerging or
433 acquired chemotherapy resistance during neoadjuvant treatment of TNBC and can also
434 synergize with *MCL1* amplification to maintain chemoresistance(Lee et al., 2017).
435 *HLA-B*, a major histocompatibility complex (MHC) class I molecule, is involved in
436 immunosurveillance against tumors and its expression is correlated with the
437 invasiveness and prognosis of breast cancer(Concha, Esteban, Cabrera, Ruiz-Cabello,

438 & Garrido, 1991). To date, there have been no reports of an association between *H3F3A*
439 or *KYAT3* and breast cancer. Previously, *H3F3A* was identified as a driver gene in
440 glioma, and its overexpression is linked to shorter survival rates and disease progression
441 in lung cancer (Felker & Broniscer, 2020; Park et al., 2016). Thus, although the
442 associations between some of the 12 mutated genes identified in our study and cancer
443 are known, their roles in the prognosis of mTNBC need to be further defined.

444 We also explored the value of ctDNA status as a biomarker for predicting the
445 prognosis and monitoring the treatment response of patients with mTNBC. We found
446 that a ctDNA+ status was associated with a worse treatment response (**Figure 3B, C**).
447 In addition, we showed that the ctDNA status at baseline could potentially discriminate
448 between mTNBC patients with a high or low lesion load (**Figure 3D**), predict their
449 prognosis (**Figure 3E**), and act as an independent prognostic factor (**Table 3**). This
450 indicates that the ctDNA status, associated with the presence of the 12 prognosis-
451 relevant mutated genes, may be a good guide to the prediction of clinical outcomes and
452 the clinical management of TNBC. We further explored the optimal cut-off values for
453 the ctDNA-based TMB, MATH score, and ctDNA% parameters at baseline using
454 Kaplan–Meier analysis. A high MATH score (≥ 6.316) and high ctDNA% (≥ 0.05) were
455 associated with a significantly shorter PFS (**Figure 4B, C**) and may therefore be related
456 to the tumor burden of mTNBC. A study reported that most ctDNA fragments originate
457 from metastases and not early-stage cancer, suggesting that ctDNA-based NGS may be
458 more suitable for the analysis of metastatic tumors (Vandekerkhove et al., 2017). Unlike
459 ctDNA%, the MATH score represents tumor heterogeneity. A previous study found that
460 TNBC was associated with a higher MATH score (Ma, Jiang, Liu, Liu, & Shao, 2017).
461 Moreover, patients with higher MATH ("Clinical practice guidelines for the use of
462 tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the
463 American Society of Clinical Oncology," 1996) scores tend to have more diverse tumor
464 cell clones and may be more prone to drug resistance and progression (McDonald et al.,
465 2019; Mroz & Rocco, 2013). Thus, the MATH score could also potentially be used as
466 a biomarker for mTNBC prognosis.

467 Breast cancer is a highly heterogeneous and dynamic disease; therefore, longitudinal

468 monitoring and management are necessary(Garcia-Murillas et al., 2015). The predictive
469 value of ctDNA has prompted further exploration of its feasibility in the dynamic
470 monitoring of the efficacy of neoadjuvant therapy for breast cancer, and in predicting
471 the occurrence of distal metastasis and drug resistance(Cavallone et al., 2020; Darrigues
472 et al., 2021; Wang et al., 2021). Here, we monitored ctDNA to track the dynamic
473 changes in the 12 identified prognosis-related genes during the treatment of patients
474 with mTNBC. The results showed that the elimination of these mutations or the
475 reduction in the mutation rate of these genes was often associated with a better
476 treatment response. Conversely, reappearance of these mutations at a later time point or
477 an increase in their mutation rate signaled disease progression. Thus, we showed that
478 the analysis of ctDNA was sensitive and accurately reflected the treatment response and
479 disease status of patients with mTNBC in a timely manner. Conventional tumor markers
480 have been widely used in clinical cancer management for some time("Clinical practice
481 guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on
482 May 17, 1996 by the American Society of Clinical Oncology," 1996). We found that,
483 the serum CEA and CA153 levels contradicted the treatment response of Patient 31 at
484 the mid-treatment time point (**Figure 5B**). The elevation of conventional tumor markers
485 could indicate changes in the tumor and could be interpreted as an early warning of
486 disease progression or pseudo-progression. However, this pseudo-progression or
487 "tumor marker spike" is actually caused by extensive neoplastic cell necrosis induced
488 by anti-tumor therapy. This phenomenon is observed in up to 30% of patients who
489 respond to treatment(Seregni, Coli, & Mazzucca, 2004). NGS-mediated ctDNA
490 detection identifies hundreds or thousands of mutations. Even if individual mutations
491 were the result of a "ctDNA spike" (similar to a "tumor marker spike"), other mutations
492 could be relied upon to accurately signal treatment efficacy. Moreover, we observed
493 positive correlations between treatment response and MATH score and ctDNA%, but
494 not the CEA, CA125, and CA153 levels (**Figure 5E**). Hence, compared with
495 conventional tumor markers, ctDNA dynamics may better reflect treatment response
496 and progression in mTNBC.

497 Several limitations exist in our study. First, this was a single-center study with a small

498 sample size. Second, the relatively short median follow-up duration was insufficient for
499 capturing a clinically significant association between ctDNA mutations and overall
500 survival. Third, several patients were lost to follow-up, which may have biased the
501 results. Fourth, the potential influence of different treatment lines and regimens was not
502 evaluated; nevertheless, no differences were found in survival based on these factors.
503 Finally, compared with whole-exome sequencing or whole-genome sequencing, NGS
504 with a panel of 457 selected genes, as used in our study, provided limited mutation data.

505

506 **Conclusions**

507 ctDNA profiling is a good alternative to tumor tissue sequencing and provides valuable
508 insights into the mutational landscape of mTNBC. Furthermore, our study addressed
509 the value of ctDNA in predicting the prognosis and monitoring the treatment response
510 of patients with mTNBC. The results revealed that higher ctDNA%, MATH score, TMB,
511 ctDNA+ status, and mutation rate were associated with a poor prognosis and a worse
512 treatment response in mTNBC. Moreover, the longitudinal monitoring of genetic
513 biomarkers in ctDNA was more sensitive and accurate for discerning treatment
514 response or progression than traditional tumor markers such as CEA, CA125, and
515 CA153. Taken together, these findings will contribute to a better understanding of
516 ctDNA in mTNBC and may facilitate the development of a more accurate and non-
517 invasive clinical strategy for managing patients with this condition. However, larger
518 clinical trials are necessary to validate our results.

519

520 **Additional information**

521 **Competing interests**

522 The authors declare no potential conflicts of interest.

523 **Funding**

Funder	Grant No.	Author
National Natural Science Foundation of China	81902713	Huihui Li
Natural Science Foundation of Shandong Province	ZR2019LZL018	Jinming Yu

Breast Disease Research Fund of Shandong Provincial Medical Association	YXH2020ZX066	Huihui Li
Start-up Fund of Shandong Cancer Hospital	2020-PYB10	Huihui Li
Beijing Science and Technology Innovation Fund	KC2021-ZZ-0010-1	Huihui Li

524 **Acknowledgments**

525 We sincerely thank the support of Yongsheng Wang, Pengfei Qiu, Binbin Cong, Peng
526 Chen, Yanbing Liu, Chunjian Wang, Zhaopeng Zhang, Tong Zhao, Xiao Sun, Zhiyong
527 Yu, Zhijun Huo, Xinzhao Wang, Shubin Song, Liang Zhang, Zhaoyun Liu, Fukai Wang,
528 Chao Li, Xiang Song, Wenshu Zuo, Hui Fu, Meizhu Zheng, Ben Yang, Chao Han, Qian
529 Shao, Xijun Liu, Jinzhi Wang, Wei Wang, Fengxiang Li, Yun Zhao, Linlin Wang,
530 Bingjie Fan, Bing Zou, Zhenhua Gao, Xiangjiao Meng, Liyang Jiang, Zhengqiang Yang
531 and Peng Xie. We also thank Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing a
532 draft of this manuscript.

533 **Ethics**

534 Human subjects: The study was approved by the Ethics Committee of Shandong Cancer
535 Hospital and Institute (approval number: SDTHEC201806003) that collection of
536 information, tumor tissues and blood samples within the ethical limitation of the patients,
537 and conducted according to the Declaration of Helsinki. Written informed consent was
538 obtained from all patients.

539 **Data Availability**

540 The raw sequence data generated during the current study have been deposited in the
541 China National Genomics Data Center (<https://ngdc.cncb.ac.cn/gsa-human/>). The data
542 under accession HRA002598 will be available on 27 June 2024 and are also available
543 from the corresponding author upon reasonable request.

544

545 **References**

- 546 Alix-Panabières, C., & Pantel, K. (2016). Clinical Applications of Circulating Tumor
547 Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov*, 6(5), 479-
548 491. doi:10.1158/2159-8290.Cd-15-1483
- 549 Asante, D. B., Calapre, L., Ziman, M., Meniawy, T. M., & Gray, E. S. (2020). Liquid

- 550 biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for
551 prime time? *Cancer Lett*, 468, 59-71. doi:10.1016/j.canlet.2019.10.014
- 552 Barroso-Sousa, R., Forman, J., Collier, K., Weber, Z. T., Jammihal, T. R., Kao, K. Z., . . .
553 Tolaney, S. M. (2022). Multidimensional Molecular Profiling of Metastatic
554 Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. *JCO*
555 *Precis Oncol*, 6, e2100413. doi:10.1200/po.21.00413
- 556 Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua,
557 S. A., . . . Brown, P. H. (2015). Comprehensive genomic analysis identifies
558 novel subtypes and targets of triple-negative breast cancer. *Clin Cancer Res*,
559 21(7), 1688-1698. doi:10.1158/1078-0432.Ccr-14-0432
- 560 Campos-Carrillo, A., Weitzel, J. N., Sahoo, P., Rockne, R., Mokhnatkin, J. V., Murtaza,
561 M., . . . Slavin, T. P. (2020). Circulating tumor DNA as an early cancer detection
562 tool. *Pharmacol Ther*, 207, 107458. doi:10.1016/j.pharmthera.2019.107458
- 563 Cavallone, L., Aguilar-Mahecha, A., Lafleur, J., Brousse, S., Aldamry, M., Roseshter,
564 T., . . . Basik, M. (2020). Prognostic and predictive value of circulating tumor
565 DNA during neoadjuvant chemotherapy for triple negative breast cancer. *Sci*
566 *Rep*, 10(1), 14704. doi:10.1038/s41598-020-71236-y
- 567 Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C., Flaum, L., Beaubier, N., . . .
568 Cristofanilli, M. (2017). Concordance of Genomic Alterations by Next-
569 Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in
570 Breast Cancer. *Mol Cancer Ther*, 16(7), 1412-1420. doi:10.1158/1535-
571 7163.Mct-17-0061
- 572 Chae, Y. K., & Oh, M. S. (2019). Detection of Minimal Residual Disease Using ctDNA
573 in Lung Cancer: Current Evidence and Future Directions. *J Thorac Oncol*, 14(1),
574 16-24. doi:10.1016/j.jtho.2018.09.022
- 575 Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., . . .
576 Frampton, G. M. (2017). Analysis of 100,000 human cancer genomes reveals
577 the landscape of tumor mutational burden. *Genome Med*, 9(1), 34.
578 doi:10.1186/s13073-017-0424-2
- 579 Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ

580 preprocessor. *Bioinformatics*, 34(17), i884-i890.
581 doi:10.1093/bioinformatics/bty560

582 Chen, S., Zhou, Y., Chen, Y., Huang, T., Liao, W., Xu, Y., . . . Gu, J. (2019). Gencore:
583 an efficient tool to generate consensus reads for error suppressing and duplicate
584 removing of NGS data. *BMC Bioinformatics*, 20(Suppl 23), 606.
585 doi:10.1186/s12859-019-3280-9

586 Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., . . . Turner, N. C.
587 (2020). Homologous recombination DNA repair deficiency and PARP
588 inhibition activity in primary triple negative breast cancer. *Nat Commun*, 11(1),
589 2662. doi:10.1038/s41467-020-16142-7

590 Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.
591 Adopted on May 17, 1996 by the American Society of Clinical Oncology.
592 (1996). *J Clin Oncol*, 14(10), 2843-2877. doi:10.1200/jco.1996.14.10.2843

593 Collier, K. A., Asad, S., Tallman, D., Jenison, J., Rajkovic, A., Mardis, E. R., . . . Stover,
594 D. G. (2021). Association of 17q22 Amplicon Via Cell-Free DNA With
595 Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.
596 *JCO Precis Oncol*, 5. doi:10.1200/po.21.00104

597 Concha, A., Esteban, F., Cabrera, T., Ruiz-Cabello, F., & Garrido, F. (1991). Tumor
598 aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
599 *Semin Cancer Biol*, 2(1), 47-54.

600 Coussy, F., Lallemand, F., Vacher, S., Schnitzler, A., Chemlali, W., Caly, M., . . . Bièche,
601 I. (2017). Clinical value of R-spondins in triple-negative and metaplastic breast
602 cancers. *Br J Cancer*, 116(12), 1595-1603. doi:10.1038/bjc.2017.131

603 Darrigues, L., Pierga, J. Y., Bernard-Tessier, A., Bièche, I., Silveira, A. B., Michel,
604 M., . . . Bidard, F. C. (2021). Circulating tumor DNA as a dynamic biomarker
605 of response to palbociclib and fulvestrant in metastatic breast cancer patients.
606 *Breast Cancer Res*, 23(1), 31. doi:10.1186/s13058-021-01411-0

607 Davis, A. A., Jacob, S., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N., . . .
608 Cristofanilli, M. (2020). Landscape of circulating tumour DNA in metastatic
609 breast cancer. *EBioMedicine*, 58, 102914. doi:10.1016/j.ebiom.2020.102914

- 610 Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F., . . .
611 Rosenfeld, N. (2013). Analysis of circulating tumor DNA to monitor metastatic
612 breast cancer. *N Engl J Med*, 368(13), 1199-1209.
613 doi:10.1056/NEJMoa1213261
- 614 Diaz, L. A., Jr., & Bardelli, A. (2014). Liquid biopsies: genotyping circulating tumor
615 DNA. *J Clin Oncol*, 32(6), 579-586. doi:10.1200/jco.2012.45.2011
- 616 Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . .
617 Verweij, J. (2009). New response evaluation criteria in solid tumours: revised
618 RECIST guideline (version 1.1). *Eur J Cancer*, 45(2), 228-247.
619 doi:10.1016/j.ejca.2008.10.026
- 620 Felker, J., & Broniscer, A. (2020). Improving long-term survival in diffuse intrinsic
621 pontine glioma. *Expert Rev Neurother*, 20(7), 647-658.
622 doi:10.1080/14737175.2020.1775584
- 623 Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer.
624 *N Engl J Med*, 363(20), 1938-1948. doi:10.1056/NEJMra1001389
- 625 Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., . . .
626 Turner, N. C. (2015). Mutation tracking in circulating tumor DNA predicts
627 relapse in early breast cancer. *Sci Transl Med*, 7(302), 302ra133.
628 doi:10.1126/scitranslmed.aab0021
- 629 Gerratana, L., Davis, A. A., Zhang, Q., Basile, D., Rossi, G., Strickland, K., . . .
630 Cristofanilli, M. (2021). Longitudinal Dynamics of Circulating Tumor Cells and
631 Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer.
632 *JCO Precis Oncol*, 5, 943-952. doi:10.1200/po.20.00345
- 633 Jiang, Y. Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., . . . Shao, Z. M. (2019). Genomic
634 and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes
635 and Treatment Strategies. *Cancer Cell*, 35(3), 428-440.e425.
636 doi:10.1016/j.ccell.2019.02.001
- 637 Kim, H., Kim, Y. J., Park, D., Park, W. Y., Choi, D. H., Park, W., . . . Kim, N. (2021).
638 Dynamics of circulating tumor DNA during postoperative radiotherapy in
639 patients with residual triple-negative breast cancer following neoadjuvant

- 640 chemotherapy: a prospective observational study. *Breast Cancer Res Treat*,
641 189(1), 167-175. doi:10.1007/s10549-021-06296-3
- 642 Kim, S., Lee, J., Jeon, M., Nam, S. J., & Lee, J. E. (2015). Elevated TGF- β 1 and - β 2
643 expression accelerates the epithelial to mesenchymal transition in triple-
644 negative breast cancer cells. *Cytokine*, 75(1), 151-158.
645 doi:10.1016/j.cyto.2015.05.020
- 646 Lee, K. M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L.,
647 Hutchinson, K. E., . . . Arteaga, C. L. (2017). MYC and MCL1 Cooperatively
648 Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of
649 Mitochondrial Oxidative Phosphorylation. *Cell Metab*, 26(4), 633-647.e637.
650 doi:10.1016/j.cmet.2017.09.009
- 651 Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with Burrows-
652 Wheeler transform. *Bioinformatics*, 25(14), 1754-1760.
653 doi:10.1093/bioinformatics/btp324
- 654 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., . . . Durbin, R.
655 (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics*,
656 25(16), 2078-2079. doi:10.1093/bioinformatics/btp352
- 657 Li, J., Lupat, R., Amarasinghe, K. C., Thompson, E. R., Doyle, M. A., Ryland, G. L., . . .
658 Goringe, K. L. (2012). CONTRA: copy number analysis for targeted
659 resequencing. *Bioinformatics*, 28(10), 1307-1313.
660 doi:10.1093/bioinformatics/bts146
- 661 Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., . . . Meisel, J. L. (2017).
662 Triple-negative breast cancer has worse overall survival and cause-specific
663 survival than non-triple-negative breast cancer. *Breast Cancer Res Treat*, 161(2),
664 279-287. doi:10.1007/s10549-016-4059-6
- 665 Lin, P. H., Wang, M. Y., Lo, C., Tsai, L. W., Yen, T. C., Huang, T. Y., . . . Huang, C. S.
666 (2021). Circulating Tumor DNA as a Predictive Marker of Recurrence for
667 Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
668 *Front Oncol*, 11, 736769. doi:10.3389/fonc.2021.736769
- 669 Ma, D., Jiang, Y. Z., Liu, X. Y., Liu, Y. R., & Shao, Z. M. (2017). Clinical and molecular

- 670 relevance of mutant-allele tumor heterogeneity in breast cancer. *Breast Cancer*
671 *Res Treat*, 162(1), 39-48. doi:10.1007/s10549-017-4113-z
- 672 Madic, J., Kiialainen, A., Bidard, F. C., Birzele, F., Ramey, G., Leroy, Q., . . . Lebofsky,
673 R. (2015). Circulating tumor DNA and circulating tumor cells in metastatic
674 triple negative breast cancer patients. *Int J Cancer*, 136(9), 2158-2165.
675 doi:10.1002/ijc.29265
- 676 Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., . . .
677 Arpino, G. (2012). Clinical and biologic features of triple-negative breast
678 cancers in a large cohort of patients with long-term follow-up. *Breast Cancer*
679 *Res Treat*, 136(3), 795-804. doi:10.1007/s10549-012-2315-y
- 680 Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S., . . .
681 Catenacci, D. V. T. (2019). Circulating Tumor DNA Sequencing Analysis of
682 Gastroesophageal Adenocarcinoma. *Clin Cancer Res*, 25(23), 7098-7112.
683 doi:10.1158/1078-0432.Ccr-19-1704
- 684 Mascia, F., Mazo, I., Alterovitz, W. L., Karagiannis, K., Wu, W. W., Shen, R. F., . . .
685 Rao, V. A. (2022). In search of autophagy biomarkers in breast cancer: Receptor
686 status and drug agnostic transcriptional changes during autophagy flux in cell
687 lines. *PLoS One*, 17(1), e0262134. doi:10.1371/journal.pone.0262134
- 688 McDonald, K. A., Kawaguchi, T., Qi, Q., Peng, X., Asaoka, M., Young, J., . . . Takabe,
689 K. (2019). Tumor Heterogeneity Correlates with Less Immune Response and
690 Worse Survival in Breast Cancer Patients. *Ann Surg Oncol*, 26(7), 2191-2199.
691 doi:10.1245/s10434-019-07338-3
- 692 Mroz, E. A., & Rocco, J. W. (2013). MATH, a novel measure of intratumor genetic
693 heterogeneity, is high in poor-outcome classes of head and neck squamous cell
694 carcinoma. *Oral Oncol*, 49(3), 211-215.
695 doi:10.1016/j.oraloncology.2012.09.007
- 696 Murtaza, M., Dawson, S. J., Tsui, D. W., Gale, D., Forshew, T., Piskorz, A. M., . . .
697 Rosenfeld, N. (2013). Non-invasive analysis of acquired resistance to cancer
698 therapy by sequencing of plasma DNA. *Nature*, 497(7447), 108-112.
699 doi:10.1038/nature12065

- 700 Ortolan, E., Appierto, V., Silvestri, M., Miceli, R., Veneroni, S., Folli, S., . . . Di Cosimo,
701 S. (2021). Blood-based genomics of triple-negative breast cancer progression in
702 patients treated with neoadjuvant chemotherapy. *ESMO Open*, 6(2), 100086.
703 doi:10.1016/j.esmoop.2021.100086
- 704 Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., . . . Silvestris,
705 F. (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical
706 oncology. *Ther Adv Med Oncol*, 10, 1758835918794630.
707 doi:10.1177/1758835918794630
- 708 Park, S. M., Choi, E. Y., Bae, M., Kim, S., Park, J. B., Yoo, H., . . . Kim, I. H. (2016).
709 Histone variant H3F3A promotes lung cancer cell migration through intronic
710 regulation. *Nat Commun*, 7, 12914. doi:10.1038/ncomms12914
- 711 Perou, C. M. (2011). Molecular stratification of triple-negative breast cancers.
712 *Oncologist*, 16 Suppl 1, 61-70. doi:10.1634/theoncologist.2011-S1-61
- 713 Poulet, G., Massias, J., & Taly, V. (2019). Liquid Biopsy: General Concepts. *Acta Cytol*,
714 63(6), 449-455. doi:10.1159/000499337
- 715 Riva, F., Bidard, F. C., Houy, A., Saliou, A., Madic, J., Rampanou, A., . . . Pierga, J. Y.
716 (2017). Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant
717 Chemotherapy in Triple-Negative Breast Cancer. *Clin Chem*, 63(3), 691-699.
718 doi:10.1373/clinchem.2016.262337
- 719 Rong, G., Yi, Z., Ma, F., Guan, Y., Xu, Y., Li, L., & Xu, B. (2020). Mutational
720 characteristics determined using circulating tumor DNA analysis in triple-
721 negative breast cancer patients with distant metastasis. *Cancer Commun (Lond)*,
722 40(12), 738-742. doi:10.1002/cac2.12102
- 723 Sato, K., & Akimoto, K. (2017). Expression Levels of KMT2C and SLC20A1
724 Identified by Information-theoretical Analysis Are Powerful Prognostic
725 Biomarkers in Estrogen Receptor-positive Breast Cancer. *Clin Breast Cancer*,
726 17(3), e135-e142. doi:10.1016/j.clbc.2016.11.005
- 727 Seregni, E., Coli, A., & Mazzucca, N. (2004). Circulating tumour markers in breast
728 cancer. *Eur J Nucl Med Mol Imaging*, 31 Suppl 1, S15-22. doi:10.1007/s00259-
729 004-1523-z

- 730 Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., . . .
731 Adalsteinsson, V. A. (2018). Association of Cell-Free DNA Tumor Fraction and
732 Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative
733 Breast Cancer. *J Clin Oncol*, 36(6), 543-553. doi:10.1200/jco.2017.76.0033
- 734 Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray,
735 F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
736 and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*,
737 71(3), 209-249. doi:10.3322/caac.21660
- 738 Swarup, V., & Rajeswari, M. R. (2007). Circulating (cell-free) nucleic acids--a
739 promising, non-invasive tool for early detection of several human diseases.
740 *FEBS Lett*, 581(5), 795-799. doi:10.1016/j.febslet.2007.01.051
- 741 Vandekerkhove, G., Todenhöfer, T., Annala, M., Struss, W. J., Wong, A., Beja, K., . . .
742 Wyatt, A. W. (2017). Circulating Tumor DNA Reveals Clinically Actionable
743 Somatic Genome of Metastatic Bladder Cancer. *Clin Cancer Res*, 23(21), 6487-
744 6497. doi:10.1158/1078-0432.Ccr-17-1140
- 745 Wang, Y., Lin, L., Li, L., Wen, J., Chi, Y., Hao, R., . . . Wang, O. (2021). Genetic
746 landscape of breast cancer and mutation tracking with circulating tumor DNA
747 in Chinese women. *Aging (Albany NY)*, 13(8), 11860-11876.
748 doi:10.18632/aging.202888
- 749 Weber, Z. T., Collier, K. A., Tallman, D., Forman, J., Shukla, S., Asad, S., . . . Stover,
750 D. G. (2021). Modeling clonal structure over narrow time frames via circulating
751 tumor DNA in metastatic breast cancer. *Genome Med*, 13(1), 89.
752 doi:10.1186/s13073-021-00895-x
- 753 Wongchenko, M. J., Kim, S. B., Saura, C., Oliveira, M., Lipson, D., Kennedy, M., . . .
754 Dent, R. (2020). Circulating Tumor DNA and Biomarker Analyses From the
755 LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for
756 Metastatic Triple-Negative Breast Cancer. *JCO Precis Oncol*, 4, 1012-1024.
757 doi:10.1200/po.19.00396
- 758 Yang, L., Perez, A. A., Fujie, S., Warden, C., Li, J., Wang, Y., . . . Yen, Y. (2014). Wnt
759 modulates MCL1 to control cell survival in triple negative breast cancer. *BMC*

760 Cancer, 14, 124. doi:10.1186/1471-2407-14-124

761 Zhang, J., Hou, S., You, Z., Li, G., Xu, S., Li, X., . . . Pang, D. (2021). Expression and
762 prognostic values of ARID family members in breast cancer. *Aging (Albany*
763 *NY)*, 13(4), 5621-5637. doi:10.18632/aging.202489

764 Zhang, Y. J., Wei, L., Liu, M., Li, J., Zheng, Y. Q., Gao, Y., & Li, X. R. (2013). BTG2
765 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-
766 negative breast cancer cells. *Tumour Biol*, 34(3), 1605-1613.
767 doi:10.1007/s13277-013-0691-5

768 Zhu, R., Yang, G., Cao, Z., Shen, K., Zheng, L., Xiao, J., . . . Zhang, T. (2020). The
769 prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer
770 therapy: a rising star. *Ther Adv Med Oncol*, 12, 1758835920940946.
771 doi:10.1177/1758835920940946

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787


788

789

790 Supplement table 1. The list of 457 genes detected in this study.

ABL1	BRCA1	CDKN2C	ERBB3	GABRA6	IRF4	MAPK8IP1	NOTCH4	POLE	RPA3	TEK
ACVR1B	BRCA2	CEBPA	ERBB4	GAGE1	IRS2	MCL1	NPM1	POLQ	RPL22	TENT5C
ACVR2A	BRD4	CHEK1	ERCC2	GALNT12	ITK	MDM2	NRAS	PPARG	RPL5	TET1
AJUBA	BRIP1	CHEK2	ERCC3	GATA1	JAK1	MDM4	NRG1	PPM1D	RPTOR	TET2
AKT1	BTG1	CIC	ERCC4	GATA2	JAK2	MECOM	NSD1	PPP2R1A	RUNX1	TGFB1
AKT2	BTG2	CREBBP	ERCC5	GATA3	JAK3	MED12	NSD2	PPP2R2A	SDHA	TGFBR2
AKT3	BTK	CRIPAK	ERG	GATA4	JUN	MEF2B	NSD3	PRDM1	SDHB	TIPARP
ALK	BTLA	CRKL	ERRFI1	GATA6	KDM5A	MEN1	NT5C2	PRF1	SDHC	TLR4
ALOX12B	EMSY	CSF1R	ESR1	GID4 (C17orf39)	KDM5C	MERTK	NT5E	PRKAR1A	SDHD	TNF
AMER1	CALR	CSF3R	ETV1	GNA11	KDM6A	MET	NTRK1	PRKCI	SETBP1	TNFAIP3
APC	CARD11	CTAG2	EZH2	GNA13	KDR	MGMT	NTRK2	PRX	SETD2	TNFRSF14
AR	CASP8	CTCF	FANCA	GNAQ	KEAP1	MITF	NTRK3	PTCH1	SF3B1	TNFRSF18
ARAF	CBFB	CTLA4	FANCC	GNAS	KEL	MKNK1	P2RY8	PTEN	SGK1	TNFRSF4
ARFRP1	CBL	CTNNA1	FANCG	GREM1	KIT	MLH1	PALB2	PTK6	SH2D1A	TNFSF11
ARHGAP35	CCND1	CTNNB1	FANCL	GRM3	KITLG	MLH3	PRKN	PTPN11	SIK1	TNFSF14
ARHGEF12	CCND2	CUL3	FANCM	GSK3B	KLHL6	MPL	PARP1	PTPRD	SIN3A	TNFSF18
ARID1A	CCND3	CUL4A	FAS	H3F3A	KMT2A	MRE11	PARP2	PTPRK	SLAMF7	TNFSF4
ARID2	CCNE1	CXCR4	FBXW7	H3F3C	KMT2B	MSH2	PARP3	PTPRO	SMAD2	TOP1
ARID5B	CD160	CYP17A1	FGF10	HAVCR2	KMT2C	MSH3	PAX5	PTPRT	SMAD4	TP53
ASXL1	CD22	DAXX	FGF12	HDAC1	KMT2D	MSH6	PBRM1	QKI	SMARCA4	TSC1
ATM	CD244	DDR1	FGF14	HDAC2	KRAS	MST1R	PCBP1	RAC1	SMARCB1	TSC2
ATR	CD274	DDR2	FGF19	HDAC3	LAG3	MTAP	PCNA	RAD21	SMC1A	TSHR
ATRX	CD276	DICER1	FGF23	HDAC6	LCK	MTOR	PDCD1	RAD50	SMC3	TSHZ2
AURKA	CD28	DIS3	FGF3	HGF	LEF1	MUTYH	PDCD1LG2	RAD51	SMO	TSHZ3
AURKB	CD38	DNMT3A	FGF4	HIST1H1C	LIFR	MYC	PDGFRA	RAD51B	SNCAIP	TYRO3
AXIN1	CD48	DOT1L	FGF6	HIST1H2BD	LIMK1	MYCL	PDGFRB	RAD51C	SOCS1	U2AF1
AXIN2	CD69	EED	FGFR1	HNF1A	LRRK2	MYCN	PKD1	RAD51D	SOX17	USP9X
AXL	CD70	EGFR	FGFR2	HRAS	LTK	MYD88	PHF6	RAD52	SOX2	VEGFA
B2M	CD79A	EGR3	FGFR3	HSD3B1	LYN	NAV3	PHOX2B	RAD54L	SOX9	VEGFB
B4GALT3	CD79B	EIF4A2	FGFR4	ICOS	MAF	NBN	PIGF	RAF1	SPATA2	VEZF1
BAGE	CD80	ELF3	FH	ICOSLG	MAGEA1	NCOA4	PIK3C2B	RARA	SPEN	VHL
BAP1	CD86	EOMES	FLCN	ID3	MAGEA12	NCOR1	PIK3C2G	RB1	SPOP	VTCN1
BARD1	CDC73	EP300	FLT1	IDH1	MAGEA3	NEK11	PIK3CA	RBM10	SRC	WT1
BCL2	CDH1	EPCAM	FLT3	IDH2	MAGEA4	NF1	PIK3CB	RECQL	STAG2	XPO1
BCL2L1	CDK12	EPHA1	FLT4	IGF1R	MAGEC2	NF2	PIK3CD	RECQL4	STAT3	XRCC2
BCL2L2	CDK4	EPHA2	FOXA1	IGF2	MAP2K1	NFE2L2	PIK3CG	REL	STK11	ZNF217
BCL6	CDK6	EPHA3	FOXA2	IKBKE	MAP2K2	NFE2L3	PIK3R1	RET	SUFU	ZNF703
BCOR	CDK8	EPHB1	FOXL2	IKZF1	MAP2K4	NFKBIA	PIK3R2	RICTOR	SYK	
BCORL1	CDKN1A	EPHB4	FOXO3	IL7R	MAP3K1	NKX2-1	PIM1	RNF43	TAF1	
BLM	CDKN1B	EPHB6	FOXP1	INPP4B	MAP3K13	NOTCH1	PMS1	ROS1	TAS2R38	
BMPR1A	CDKN2A	EPPK1	FRK	INSR	MAPK1	NOTCH2	PMS2	RPA1	TBL1XR1	
BRAF	CDKN2B	ERBB2	FUBP1	IRF2	MAPK11	NOTCH3	POLD1	RPA2	TBX3	

Supplementary Figure 1



791

792

793

794

795


796

797

798

Supplementary Figure 1. (A) Kaplan–Meier analysis of PFS in all patients with mTNBC. (B) Kaplan–Meier analysis of PFS in patients with different lines of treatment. (C–H) Kaplan–Meier analysis of PFS in patients treated with distinct treatment regimens. GP, gemcitabine- and platinum-based treatment; IC, immunotherapy plus chemotherapy; mTNBC, metastatic triple-negative breast cancer; P, platinum-based treatment; PFS, progression-free survival; T, taxane-based treatment; TP, taxane- and platinum-based treatment. A P -value < 0.05 was used as a measure of statistical significance.


Supplementary Figure 2



799

800 **Supplementary Figure 2. Comparison of mutation frequency between ctDNA and tissue.** The mutation
801 frequency in ctDNA was significantly lower than that in tissues ($P < 0.001$). ctDNA, circulating tumor DNA. A P -
802 value < 0.05 was used as a measure of statistical significance.

Supplementary Figure 3



803

804

805

806

807

808

Supplementary Figure 3. Kaplan–Meier analysis of the PFS of 12 prognosis-relevant mutated genes in patients with mTNBC. Patients with mutated *HLA-B* (A), *MYC* (B), *CD22* (C), *BTG2* (D), *KMT2C* (E), *TGFB1* (F), *MCL1* (G), *KYAT3* (H), *SGK1* (I), *H3F3A* (J), *ARID4B* (K), or *RSPO2* (L) had a significantly shorter PFS. Gain = copy number gain; mTNBC, metastatic triple-negative breast cancer patients; Mut, mutated; PFS, progression-free survival. WT, wild type. A P -value < 0.05 was used as a measure of statistical significance.